1. Abraham J, Reed T (2003) Reshaping the carcinogenic risk assessment of medicines: international harmonization for drug safety, industry/regulator efficiency or both? Social Sci Med 57: 195–204
2. Alden CL, Lynn A, Bourdeau A, Morton D, Sistare FD et al (2011) A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet Pathol 48(3):772–84
3. Auerbach SS, Shah RR, Mav D, Smith CS, Walker NJ, Vallant MK, Boorman GA, Irwin RD (2010) Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 243:300–314
4. Bergman K, Olofsson I, Sjöberg P (1998) Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat. Regul Toxicol Pharmacol 28:226–229
5. Bolognani F, Lempiainen H, Arne M, Philippe C, Dubost V, Luisier R, Thomson J, Unterberger E, Hahne F, Brasa S, Zollinger T, Marcellin M, Marlowe J, Oakeley E, Schubeler D, Schwarz M, Meehan R, Ellinger-Ziegelbauer H, Wolf R, Theil D, Heard D, Moulin P, Grenet O, Moggs J, Terranova R (2012) Comprehensive mapping of transcriptional and epigenetic perturbations in vivo identifies noncoding RNAs as novel biomarkers for liver tumor promotion, 82. The Toxicologist CD, Society of Toxicology, San Francisco, CA, 11 March 2012, p 126